AbCellera Biologics (8QQ) Stock Statistics & Valuation Metrics

AbCellera Biologics has a market cap or net worth of €936.77M. The enterprise value is €1.08B.

AbCellera Biologics has 303,160,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

AbCellera Biologics’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -13.78%.

The current PE Ratio of AbCellera Biologics is ―. AbCellera Biologics’s PEG ratio is 0.64.

In the last 12 months, AbCellera Biologics had revenue of 75.13M and earned -146.41M in profits. Earnings per share was -0.49.

In the last 12 months, operating cash flow was -131.29M and capital expenditures -42.77M, giving a free cash flow of -174.07M billion.

AbCellera Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

AbCellera Biologics upcoming earnings date is May 7, 2026, After Close (Confirmed).

AbCellera Biologics as a current ratio of 11.32, with Debt / Equity ratio of 12.55%

In the past 12 months, AbCellera Biologics has paid -31.18M in taxes.

AbCellera Biologics EV to EBITDA ratio is -6.50, with an EV/FCF ratio of -5.80.

AbCellera Biologics has €560.33M in cash and marketable securities with €143.22M in debt, giving a net cash position of €417.11M billion.

Gross margin is 100.00%, with operating margin of -288.98%, and net profit margin of -194.88%.

The average price target for AbCellera Biologics is €6.03, which is 11.43% higher than the current price. The consensus rating is Strong Buy